

**Deanship of Graduate Studies  
Al-Quds University**



**Alloimmunization among Transfusion-Dependent  
Thalassemia Patients in the West Bank**

**Hammam A. H. Ali**

**M.Sc. Thesis**

**Jerusalem-Palestine**

**1440/2018**

# **Alloimmunization among Transfusion-Dependent Thalassemia Patients in the West Bank**

Prepared By:  
**Hammam A. H. Ali**

B.Sc. Medical Technology, Al-Quds University- Palestine

Supervisor: Dr. Adham Abu Taha  
Co-Supervisor: Dr. Khalid Younis

A thesis submitted in partial fulfillment of required for the  
degree of master of medical laboratory sciences program,  
hematology track- Al-Quds university

**1440/2018**

Al-Quds University  
Deanship of Graduate Studies  
Medical Laboratory Sciences Program



## Thesis Approval

### Alloimmunization among Transfusion-Dependent Thalassemia Patients in the West Bank

Prepared By: Hammam A. H. Ali  
Registration No: 21512321

Supervisor: Dr. Adham Abu Taha  
Co-Supervisor: Dr. Khalid Younis

Master Thesis Submitted and Accepted, Date 2018/11/10  
The Names and Signatures of the Examining Committee Members are as  
Follows

Head of Committee: Dr. Adham Abu Taha  
Internal Examiner: Dr. Rania Abu Seir  
External Examiner: Dr. Fikri Samarah  
Committee Member: Dr. Khalid Younis

Signature:

Signature:

Signature:

Signature:

Jerusalem-Palestine

1440 Hijri/2018 AD

## **Dedication**

This thesis is dedicated to the following people:

My great parents, Aysha and Abdelrahman, who never stopped giving of themselves in countless ways.

My dearest wife, Sanaa, who led me through the valley of darkness with the light of hope and support.


My beloved brothers and sister; particularly my great brother Husni, who stood by me when things looked bleak.

All of the thalassemia patients in Palestine, who needed this re

**Declaration:**

I Certify That This Thesis Submitted for The Degree of Master, is The Result of My Own Research, Except Where Otherwise acknowledged, and That This Study (or Any Part of The Same) Has Not Been Submitted for A Higher Degree to Any Other University or Institute.

Signed:



Hammam A. H. Ali

Date:2018/ 11/10

## **Acknowledgements**

At the beginning, I am grateful to Allah for the good health and wellbeing that were necessary to complete this thesis.

I would like to thank my advisors, Dr. Aham Abu Taha and Dr. Khalid Younis. Their offices were always open whenever I ran into trouble or had a question about my research or writing. They consistently allowed this paper to be my own work but steered me in the right direction whenever they thought I needed it.

I would also like to thank my colleagues in transfusion centers and related blood banks, I am gratefully indebted to them for their very valuable helped in sample collection. In addition, I would like to thank Dr. Bashar Alkarmi from Palestinian Thalassemia Patients Friends Society.

Last but not least, I must express my very profound gratitude to my family; my parents, my brothers, my sister, and my wife for providing me with unfailing support and continuous encouragement throughout my years of study and through the process of researching and writing this thesis. This accomplishment would not have been possible without them.

## **Abstract**

### **Introduction:**

Red blood cell transfusion has greatly reduced the mortality and morbidity in multiply transfused thalassemia patients. However, this can result in red blood cell isoimmunization with alloantibodies which can lead to serious complications such as acute and delayed hemolytic transfusion reactions.

### **Objectives:**

To assess the frequency and types of alloantibodies in transfusion-dependent thalassemia patients in the middle and southern regions of the West Bank. Furthermore, to assess the association between alloantibody development and gender, age of first transfusion, blood type, splenectomy, frequency of transfusion.

### **Methods:**

This cross-sectional study was performed between February and June, 2017 at three Thalassemia Centers in the southern and middle districts of the West Bank. A total of 101 transfusion-dependent thalassemia patients from these centers were included. Clinical and transfusion records were examined for age of patients, age at first transfusion therapy, total number of blood units transfused, and the status of spleen. Alloantibody screening and identification was also performed by using the gel card method (Diamed ID, Switzerland).

### **Results:**

Eleven out of one hundred and one participants (10.9%) had alloantibodies. Ten of them (90.9%) were diagnosed with  $\beta$ -thalassemia major, and one (9.1%) was diagnosed with  $\beta$ -thalassemia intermedia. The majority of alloimmunized patients were females (8; 72.7%).

Eight patients (72.7%) were splenectomized. Seven patients (63.6%) had single alloantibody, while four (36.4%) developed multiple alloantibodies.

Six types of alloantibodies were identified, three (50%) were against antigens from the Rh system (anti-E, anti-C and anti-D), two (33.3%) were against antigens from the Kell system (anti-K and anti-Kp<sup>a</sup>) and one (16.7%) was against an antigen from the Kidd-system (anti-Jk<sup>a</sup>).

**Conclusions:**

This data showed quite high alloimmunization rate among transfusion-dependent thalassemia patients in the middle and southern regions of the West Bank. The most frequently detected alloantibodies were against the Rh and Kell antigens.

In order to reduce the alloimmunization in these patients, a policy to perform extended red cell phenotyping of the patients and issuing antigen-matched blood should be adopted.



## **Table of Content**

<b>DECLARATION .....</b>	<b>I</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>II</b>
<b>ABSTRACT .....</b>	<b>III</b>
<b>TABLE OF CONTENT .....</b>	<b>V</b>
<b>LIST OF TABLES.....</b>	<b>VIII</b>
<b>LIST OF FIGURES.....</b>	<b>IX</b>
<b>LIST OF APPENDICES .....</b>	<b>X</b>
<b>LIST OF ABBREVIATIONS.....</b>	<b>XI</b>
 <b>CHAPTER ONE</b>	
<b>1. INTRODUCTION .....</b>	<b>1</b>
1.1. PROBLEM STATEMENT .....	4
1.2. STUDY JUSTIFICATION .....	5
1.3. OBJECTIVE.....	5
1.3.1. Main objective .....	5
1.3.2. Specific objectives.....	5
1.4. HYPOTHESES.....	5
 <b>CHAPTER TWO</b>	
<b>2. LITERATURES REVIEW .....</b>	<b>6</b>
2.1. INTRODUCTION .....	6
2.2. HISTORY OF TRANSFUSION .....	6
2.3. BLOOD GROUP SYSTEMS .....	9
2.4. PRETRANSFUSION TESTING.....	10
2.4.1. Antiglobulin Test.....	10
2.4.2. Crossmatch .....	13
2.4.3. Antibody Identification .....	12
2.5. RISKS ASSOCIATED WITH TRANSFUSION .....	12
2.5.1. Acute Transfusion Reactions.....	14

2.5.2. Delayed Transfusion Reaction.....	13
2.6. ALLOIMMUNIZATION .....	14
2.6.1. Clinical Predictors of Alloimmunization.....	16
2.6.2. Mechanism of Erythrocyte Alloimmunization .....	16
2.7. THALASSEMIA AND CHRONIC BLOOD TRANSFUSION.....	18
2.7.1. Normal Hemoglobin.....	17
2.7.2. Thalassemia Pathophysiology .....	21
2.8. TREATMENT OF THALASSEMIA .....	23
2.8.1. Chronic Blood Transfusion .....	23
2.8.2. Allogeneic Hematopoietic Stem Cell Transplantation .....	23
2.8.3. Gene Therapy .....	24
2.9.RELATED STUDY.....	25

### **CHAPTER THREE**

<b>3. MATERIALS AND METHODS.....</b>	<b>29</b>
3.1. STUDY DESIGN.....	29
3.2. STUDY POPULATION AND SAMPLE SIZE.....	30
3.3. INCLUSION AND EXCLUSION CRITERIA .....	30
3.4. ETHICAL CONSIDERATIONS .....	31
3.5. DATA COLLECTION .....	31
3.6. LABORATORY INVESTIGATIONS.....	32
3.6.1. ABO and Rh-D Identification.....	32
3.6.2. Alloantibody Screening .....	33
3.6.3. Alloantibody Identification.....	34
3.7. STATISTICAL ANALYSIS.....	34

### **CHAPTER FOUR**

<b>4. RESULTS .....</b>	<b>35</b>
4.1. PARTICIPANTS CHARACTERISTICS .....	35
4.2. ANTIBODY SCREENING .....	37
4.3. ANTIBODY IDENTIFICATION.....	38
4.4. ASSOCIATION BETWEEN CHARACTERISTICS OF PARTICIPANTS AND ALLOIMMUNIZATION .....	39
4.4.1. Governorates (Blood Transfusion Centres).....	39
4.4.2. Gender .....	40
4.4.3. Age .....	41
4.4.4. Status of Spleen .....	42
4.4.5. Age of first blood transfusion.....	42
4.4.6. Frequency of transfusion .....	43
4.4.7. Number of transfusion .....	44
4.4.8. ABO/Rh-D blood group .....	44

## **CHAPTER FIVE**

<b>5. DISCUSSION .....</b>	<b>46</b>
----------------------------	-----------

## **CHAPTER SIX**

<b>6. SUMMARY.....</b>	<b>51</b>
------------------------	-----------

6.1. CONCLUSIONS .....	51
------------------------	----

6.2. LIMITATIONS .....	52
------------------------	----

6.3. RECOMMENDATIONS .....	52
----------------------------	----

<b>REFERENCES .....</b>	<b>53</b>
-------------------------	-----------

<b>APPENDICES.....</b>	<b>56</b>
------------------------	-----------

<b>المخلص .....</b>	<b>63</b>
---------------------	-----------

## List of Tables

<b><u>Table 3.1:</u></b> Distribution of sample in terms of transfusion centres.....	31
<b><u>Table 4.1:</u></b> Distribution of the thalassemia phnyotypes of participants.....	35
<b><u>Table 4.2:</u></b> Distribution of ABO among participants.....	36
<b><u>Table 4.3:</u></b> Distribution of Rh-D antigen among participants .....	36
<b><u>Table 4.4:</u></b> Alloantibodies detected among study participants .....	39
<b><u>Table 4.5:</u></b> Alloimmunized participants according to governorate with P-value .....	40
<b><u>Table 4.6:</u></b> Association between alloimmunization and gender .....	41
<b><u>Table 4.7:</u></b> Association between alloimmunization and age .....	41
<b><u>Table 4.8:</u></b> Association between alloimmunization and frequency of transfusion .....	43
<b><u>Table 4.9:</u></b> Association between alloimmunization and number of transfusions .....	44
<b><u>Table 4.10:</u></b> Association between alloimmunization and ABO blood group .....	45
<b><u>Table 4.11:</u></b> Association between alloimmunization and status of D antigen.....	45

## List of Figures

<b>Figure 2.1:</b> General structure of hemoglobin A1.....	20
<b>Figure 2.2:</b> Structure of hemoglobin; Primary, Secondary, Tertiary and Quaternary Structures.....	20
<b>Figure 2.3:</b> Structure of hem group. ....	21
<b>Figure 4.1:</b> Distribution of gender of participants. ....	35
<b>Figure 4.2:</b> Number of transfusions of participants. ....	37
<b>Figure 4.3:</b> Distribution of Status of spleen.....	37
<b>Figure 4.4:</b> Distribution of alloimmunized participants according to gender.....	40
<b>Figure 4.5:</b> Alloimmunized participants according to status of spleen. ....	42
<b>Figure 4.6:</b> Alloimmunized participants according to age of starting transfusion. ....	43

## List of Appendices

Appendix 1: Blood group systems- Part one.	56
Appendix 2: Blood Group Systems- Part two.	57
Appendix 3: IRB Ethical Approve	58
Appendix 4: Consent Form	59
Appendix 5: Questioner	60
Appendix 6: characteristics of alloimmunized participants	61
Appendix 7: Participants' demographic	62

## List of Abbreviations

AHG: Anti-Human Globulin

ATP: Adenosine Tri-Phosphate

ATR: Acute Transfusion Reaction.

CPD: Citrate Phosphate Dextrose

CPDA: Citrate Phosphate Dextrose Adenine.

DAT: Direct Anti-globulin Test

DHTR: Delayed Hemolytic Transfusion Reaction

DTR: Delayed Transfusion Reaction.

EDTA: Ethylene Diamine Tetraacidic Acid

ESR: Erythrocyte Sedimentation Rate .

FDA: Food and Drugs Administration

GVHR: Graft Versus Host Reaction

HLA: Human leukocyte antigen

IAT: Indirect Anti-globulin Test

IgG: Immunoglobulin G

ISBT: International Society of Blood Transfusion

LISS: Low Ionic Strength Saline.

## الكشف عن الاجسام المضادة لمولدات الضد الغربية عند مرضى فقر دم حوض البحر الابيض المتوسط في الضفة الغربية

اعداد: همام عبد الرحمن حسني علي

اشراف: د. أدهم أبو طه

مشرف ثاني: د. خالد يونس

### الملخص

#### مقدمة:

إن نقل الدم من شأنه أن يقلل بشكل ملحوظ من مضاعفات ومخاطر مرض فقر دم حوض البحر الأبيض المتوسط (الثلاسيما). لكن مرضى الثلاسيما بحاجة إلى نقل دم بشكل دوري ومستمر وهذا قد يؤدي إلى تكون أجسام مضادة (Alloantibody) ضد مولدات الضد الغربية ( Foreign Antigens) التي تحملها خلايا الدم الحمراء في الدم المنقول للمرضى.

هذه الأجسام المضادة المتكونة قد تؤدي إلى مضاعفات خطيرة تقلل من درجة استفادة المريض من الدم المنقول وقد تصل المضاعفات إلى درجة قد تشكل خطورة على حياة المريض.

#### الأهداف:

تهدف هذه الدراسة الى تحديد نسبة تكون الاجسام المضادة (Alloantibody) لدى مرضى الثلاسيما في جنوب و وسط الضفة الغربية في فلسطين وتحديد انواعها الاكثر انتشارا و تحديد العلاقة بين تكون مثل هذه الاجسام المضادة و عوامل مختلفة كالجنس و العمر عند اول عملية نقل دم و نوع الدم و حالة استئصال الطحال.

#### طريقة العمل:

تم عمل هذه الدراسة في الفترة الممتدة من شهر شباط من عام 2017 وحتى حزيران من العام نفسه في ثلاث مراكز لمرضى الثلاسيما في جنوب ووسط الضفة الغربية.

تم جمع 101 عينة حيث تم دراسة المعلومات السريرية والكلينيكية للمرضى كالعمر ومعدل فترات نقل الدم والعمر عند اول عملية نقل للدم وحالة استئصال الطحال بالإضافة الى نوع الدم. وتم الكشف



عن وجود الاجسام المضادة من عدمه في عينات المرضى المشاركين في الدراسة وايضا تم تحديد انواع هذه الاجسام المضادة.

### النتائج

وجد ان 11 عينة من أصل 101 عينة مشاركة في الدراسة تحوي اجسام مضادة (10.9%) اغلبهم كان من الاناث (8;72.7%)، وايضا كان 8 من الذي يحملون اجسام مضادة (72.7%) تم استئصال الطحال لديهم سابقا.

من الذين يحملون اجسام مضادة، 7 (63.6%) كانوا يحملون نوع واحد من الاجسام المضادة، و 4 (36.4%) يحملون نوعين من الاجسام المضادة او اكثر.

تم تحديد 6 انواع مختلفة من الاجسام المضادة ثلاثة منهم تعود لنظام Rh واثنان يعودان لنظام Kell اما النوع الاخير فكان يعود لنظام Kidd.

### الخلاصة

اظهرت النتائج ارتفاعا في معدل الاجسام المضادة لدى مرضى التلاسيميا الذين يعتمدون في علاجهم على نقل الدم. وكانت الاجسام المضادة الاكثر شيوعا تلك التي ننتمي الى نظامي Rh و Kell. ومن اجل العمل على الحد من مثل هذه الاجسام المضادة فاننا نوصي باتباع سياسات تطابق اوسع في نقل الدم لهؤلاء المرضى ولا سيما تطابق مولدات الاجسام المضادة من نظامي Rh و Kell.